What is the prevalence of CDKL5?

TL;DR: CDKL5 deficiency disorder (CDD) is a rare genetic condition with an estimated prevalence between 1 in 40,000 and 1 in 60,000 individuals. While incidence figures vary, the disorder is increasingly recognized as a significant cause of early-onset refractory epilepsy, though true global prevalence remains difficult to pinpoint due to historical underdiagnosis.

What is the prevalence and incidence of CDKL5?

CDKL5 deficiency disorder is classified as a rare disease. Because it was only identified as a distinct clinical entity relatively recently, robust epidemiological data is still emerging. Current estimates suggest a prevalence of approximately 1 in 40,000 to 60,000 live births. It is important to note that these figures likely underestimate the true population, as advancements in genetic testing are identifying cases that were previously misdiagnosed as other forms of epilepsy or neurodevelopmental delay.

Does CDKL5 affect genders and age groups differently?

The CDKL5 gene is located on the X chromosome. While both males and females are affected, the clinical presentation is often more severe in males due to the lack of a second X chromosome to compensate for the mutation. CDKL5 deficiency typically presents in early infancy, usually within the first three months of life, with severe, drug-resistant seizures. While it is a lifelong condition, it is primarily diagnosed during the pediatric years, though as diagnostic access improves, more adults are receiving long-overdue CDKL5 diagnoses.

Why is accurate CDKL5 data challenging to capture?

Several factors contribute to the difficulty in determining the exact frequency of CDKL5:

• Diagnostic Gaps: In many regions, access to comprehensive genetic panels remains limited.


• Clinical Mimicry: Symptoms often overlap with Dravet syndrome, Rett syndrome, or other encephalopathies.


• Reporting Bias: Rare disease registries often capture only those with access to specialized care centers.

How does the DiseaseMaps community reflect these stats?

Real-world data provides a critical lens for understanding CDKL5. At DiseaseMaps.org, 71 people with CDKL5 have joined the community, sharing their lived experiences. This community data highlights that while CDKL5 is statistically rare, the global patient experience is unified by the need for better awareness, earlier genetic screening, and targeted therapeutic interventions.

Next steps

• Consult a clinical geneticist to discuss the latest diagnostic panel options for CDKL5.


• Connect with the CDKL5 community on DiseaseMaps.org to share experiences and resources.


• Monitor clinical trial registries (such as ClinicalTrials.gov) for research regarding CDKL5 gene therapies.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): CDKL5 deficiency disorder.


• Orphanet: CDKL5 deficiency disorder (ORPHA:391338).


• OMIM (Online Mendelian Inheritance in Man): #300672 CDKL5-related disorders.


• International CDKL5 Disorder Foundation: Clinical and research resources.